Zimbabwe has declined a significant American healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to Washington's demand for confidential data.
This move became public following a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "unbalanced".
A government representative later explained that the US was seeking health data for research and profit while refused to guarantee the resulting advantages from future treatments.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged further dialogue to secure a agreement acceptable to all parties so the nation's critical HIV programme can continue.
Broader Background
This development comes after a similar situation in Kenya, where a court halted a related deal with the US after concerns were raised about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its spending was "wasteful" and his government was seeking direct bilateral agreements to boost transparency and accountability.
As per statements, 16 nations in Africa have so far signed similar agreements, representing over $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration might have yielded extraordinary advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the arrangement was "unequal".
"Our nation was requested to share its biological resources and data for a long time, without any equivalent assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," he stated.
"Effectively, our country would supply the basic resources for scientific discovery with no certainty that the resulting innovations would be available to our people if a new pandemic emerge."
Sovereignty and Global Health
He also noted that the US's withdrawal from the global health body and its push of bilateral deals were disrupting frameworks previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This framework is intended to ensure that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as anti-American sentiment," he added.
"We encourage ongoing discussions with our American counterparts on how subsequent co-operation could be designed in a way that honours the independence and interests of each country."
Medical Community Reaction
A leading public health body stated it acknowledged the government's concerns, but recommended that talks should continue considering a large portion of the country's Aids initiatives depended on international support.
"In cases where specific concerns exist, including those relating to data governance or implementation frameworks, these can frequently be addressed through detailed discussion and negotiated safeguards," it commented.
This impasse highlights the ongoing tensions between accepting much-needed international aid and safeguarding local interests in an ever more data-driven world.